Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Castle Biosciences, Inc. Common Stock

CSTL

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Last trade $32.90
Day change +$0.15 (+0.46%)
Day range $32.70 – $34.16
Volume 174,687
Market cap $1.01B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.01B
Price / earnings
—
Price / book
2.11×
Price / sales
2.68×
EV / sales
2.5×
EV / EBITDA
-77.95×

Profitability

Earnings per share
-$0.75
Return on assets
-3.97%
Return on equity
-4.81%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.02×
Current ratio
5.28×
Quick ratio
5.12×
Cash ratio
1.15×

Cash flow

Price / cash flow
25.4×
Price / free cash flow
254.68×
Free cash flow
$3.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CSTL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$102.89M$103.55M$83.68M$87.01M$83.04M$86.19M$87.99M$86.31M
Cost of revenue$23.92M$23.7M$20.53M$18.32M$18.7M$17.63M$16.38M$16.18M
Gross profit$78.97M$79.85M$63.15M$68.7M$64.34M$68.56M$71.61M$70.13M
Selling, general and administrative$63.79M$66.12M$64.9M$56.73M$55.91M$58.07M$58.62M$49.97M
Research and development$15.81M$14.54M$14.43M$13.52M$12.96M$12.79M$12.59M$11.77M
Total operating expenses$81.7M$82.92M$81.55M$72.52M$71.14M$72.81M$99.53M$66.08M
Operating income-$2.73M-$3.07M-$18.41M-$3.83M-$6.8M-$4.25M-$27.93M$4.05M
Interest expense-$197K-$193K-$134K-$24K-$24K-$21K-$17K-$92K
Income before taxes-$3.8M-$1.69M-$14.41M-$2.71M-$386K-$143K-$26.27M$7.89M
Income taxes$298K$370K$109K-$382K$115K-$4.67M-$423K-$1.71M
Net income-$4.1M-$2.06M-$14.52M-$2.33M-$501K$4.52M-$25.85M$9.59M
Net income attributable to common shareholders-$4.1M-$2.06M-$14.52M-$2.33M-$501K$4.52M-$25.85M$9.59M
EBITDA$1.45M$1M-$14.48M-$50K-$2.99M-$837K$1.84M$9.82M
Basic earnings per share-$0.13-$0.07-$0.49-$0.08-$0.02$0.16-$0.90$0.34
Diluted earnings per share-$0.13-$0.07-$0.49-$0.08-$0.02$0.15-$0.90$0.31

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade

Castle Biosciences (CSTL) stock has gained 5% over the past four weeks and trades at $34.38. Wall Street analysts have a mean price target of $47.10, suggesting a potential 37% upside. The stock has received a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions with a 35.7% increase over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

Zacks Investment Research

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates

Castle Biosciences reported a Q3 loss of $0.13 per share, beating consensus estimates of $0.38 loss by 65.79%. Revenue reached $102.89 million, surpassing estimates by 11.84% and growing 23.9% year-over-year. The company has beaten consensus estimates four consecutive quarters. However, CSTL shares have underperformed the market, down 8.1% year-to-date versus S&P 500's 12.3% gain. The stock received a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.

Investing.com

Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon

Heather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.

GlobeNewswire Inc.

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Castle Biosciences announced results from the largest prospective multicenter study of its DecisionDx-Melanoma i31-SLNB test, presented at SSO 2026. The study of 912 patients found that patients predicted to have less than 5% risk of sentinel lymph node positivity had an actual positivity rate of 2.6%, with only 1.4% in T1b-T2a tumors. Low-risk patients demonstrated 97.8% three-year recurrence-free survival, supporting the test's ability to identify patients who may safely forgo sentinel lymph node biopsy.

GlobeNewswire Inc.

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Castle Biosciences published a prospective validation study in the Journal of the American Academy of Dermatology showing that its AdvanceAD-Tx gene expression profile test can identify patients with moderate-to-severe atopic dermatitis who are significantly more likely to achieve faster and deeper clinical responses with JAK inhibitor therapy. Approximately 30% of patients studied had a JAK Inhibitor Responder Profile and were 5.5 times more likely to achieve EASI-90 improvement by three months compared to those on Th2-targeted therapies (45.5% vs. 8.3%). The test launched in limited commercial access in late 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.